Physician profile
Mark J Charman
NPI 1033197637
$5,899.43
in general payments reported to CMS, 2019-2025
38 companies · $1,292 in 2025
The $1,292 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $102 · 2021: $587 · 2022: $729 · 2023: $1,032 · 2024: $1,309 · 2025: $1,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,633.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $968.91 | 2019-2025 | |
| Amgen INC. | $776.85 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $631.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $606.17 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $406.60 | 2021-2025 | Linzess, Viberzi, Vraylar |
| Astrazeneca Pharmaceuticals LP | $356.41 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $227.97 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $190.59 | 2019-2025 | Spravato, Xarelto |
| Axsome Therapeutics, INC. | $180.44 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $148.78 | 2019-2023 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.42 | 2019-2024 | Xifaxan |
| Esperion Therapeutics, INC. | $129.12 | 2023-2025 | Nexletol |
| Idorsia Pharmaceuticals US INC | $108.71 | 2023-2025 | Quviviq, Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.61 | 2019-2022 | |
| Glaxosmithkline, LLC. | $90.96 | 2019-2025 | Shingrix, Arexvy |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Charman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.